<DOC>
	<DOCNO>NCT03092375</DOCNO>
	<brief_summary>The study enroll well-compensated cirrhotic well non-cirrhotic subject treatment experience NS5a Inhibitor + sofosbuvir include patient complete prescribed duration due adverse event reason non/poor compliance . Subjects randomize 12 16 week treatment .</brief_summary>
	<brief_title>Phase 3b , Multi-Center , Randomized , Open-Label Study G/P +/- RBV NS5A + SOF Previously Treated GT1 HCV Subjects</brief_title>
	<detailed_description>The primary purpose study compare efficacy safety glecaprevir pibrentasvir ( G/P ) 12 week G/P 16 week non-cirrhotic NS5A ( non-structural protein 5a ) -inhibitor plus sofosbuvir ± RBV ( Ribavirin ) treatment-experienced adult HCV genotype 1 ( GT1 ) infection , compare efficacy safety G/P RBV 12 week G/P without RBV 16 week NS5A-inhibitor plus sofosbuvir ( SOF ) ± RBV treatment-experienced adult compensate cirrhosis GT1 infection .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Male female least 18 year age time screen . 2 . A history previous treatment NS5Ainhibitor plus sofosbuvir therapy ± RBV chronic HCV genotype 1 infection . 3 . Treatment must complete least 1 month prior Screening Visit . 4 . Screening laboratory result indicate chronic HCV GT1 infection . Subjects must able understand adhere study visit schedule protocol requirement must voluntarily sign date inform consent . 1 . History severe , lifethreatening significant sensitivity drug . 2 . Female pregnant , plan become pregnant study breastfeeding ; male whose partner pregnant planning become pregnant study . 3 . Recent ( within 6 month prior study drug administration ) history drug alcohol abuse could preclude adherence protocol opinion investigator . 4 . Positive test result Screening hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody ( HIV Ab ) patient without known history HIV infection . 5 . HCV genotype perform screen indicate coinfection one HCV genotype . 6 . History presence liver decompensation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HCV</keyword>
	<keyword>Previously treat</keyword>
</DOC>